noscript

News and Announcements

Novogen Edison Investment Research Report

  • Published May 23, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Novegen (ASX: NRT) is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. Headquartered in Sydney, Australia, Novogen collaborates with leading scientists, clinicians, and investors around the world. Novogen’s recent market updates presented mixed news for investors.

KEY TAKEAWAYS:

  • Recruitment in the Cantrixil Phase I is underway and preparations for the Phase II trial.
  • Mixed data from preclinical studies have seen development terminated for Anisina, which had been expected to enter the clinic in H217.
    • While the termination of Anisina is disappointing, it is encouraging to see that management is taking a disciplined approach to assessing pipeline products.
  • Now valued, Novogen is between A$86m (A$0.18/share) and A$146m (A$0.30/share) under two different development scenarios for GDC-0084.
  • Major milestones anticipated in 2017 include initiation of a Phase II trial of GDC-0084 and full enrolment in the Cantrixil Phase I.

More Information

Request Information

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now